Getting Real with RWE
By Taren Grom Real-world evidence, important for regulatory decision-making, is beginning to touch all areas…
Certara2020年11月20日
SNDS: Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU
In this webinar, our experts provided an overview of the SNDS and the key working…
Certara2020年10月20日
Payment Pressures in U.S. Specialty: Status quo and outlook for future financing
To allow for the optimal positioning of your product, portfolio, or company, it is critical…
Certara2020年9月15日
The Rare Disease Drug Dilemma: Great Value, High Price, Limited Access?
This webinar will explain how pricing has evolved for the rare disease drug market and…
Certara2020年2月19日
Using Model-based Meta-analysis to Inform Neuropathic Pain Drug Development
Model-based Meta-analysis is a framework to compare drugs used to treat diabetic peripheral neuropathy, post-herpetic…
Certara2019年12月19日
ICER’s Unsupported Drug Price Increase Report: An Analysis
We analyze the drug-price watchdog, ICER’s (Institute for Clinical and Economic Review) “Report on Unsupported…
Certara2019年10月24日
Innovative Solutions for Fast-Tracking Drugs for Rare Diseases
This webinar discussed which pharmaceutical payer strategies work and which don't in our rapidly changing…
Certara2019年8月10日
Evidence and Access Overview
Discover Certara’s holistic approach to market access.
Certara2019年5月21日
